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Abstract
Introduction: Embryonic stem cells and induced pluripotent stem cells have emerged as the gold
standard of pluripotent stem cells and the class of stem cell with the highest potential for
contribution to regenerative and therapeutic application; however, their translational use is often
impeded by teratoma formation, commonly associated with pluripotency. We discuss a population
of nontumorigenic pluripotent stem cells, termed Multilineage Differentiating Stress Enduring
(Muse) cells, which offer an innovative and exciting avenue of exploration for the potential
treatment of various human diseases.
Areas covered: This review discusses the origin of Muse cells, describes in detail their various
unique characteristics, and considers future avenues of their application and investigation with
respect to what is currently known of adult pluripotent stem cells in scientific literature. We begin
by defining cell potency, then discuss both mesenchymal and various reported populations of
pluripotent stem cells, and finally delve into Muse cells and the characteristics that set them apart
from their contemporaries.
Expert opinion: Muse cells derived from adipose tissue (Muse-AT) are efficiently, routinely
and painlessly isolated from human lipoaspirate material, exhibit tripoblastic differentiation both
spontaneously and under media-specific induction, and do not form teratomas. We describe
qualities specific to Muse-AT cells and their potential impact on the field of regenerative medicine
and cell therapy.
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1. Introduction
Since their discovery over a century ago by German scientist Ernst Haeckel, stem cells, or
stammzellen as he coined them, have dominated both scientific conversations and resources
without contest [1-3]. Alongside the discovery of their capacity for self-renewal, definitions
of cell potency, the ability of a cell to differentiate into various cell types, soon arose to
classify different types of stem cells and their ability to give rise to adult tissues of the three
embryonic germ cell lineages. The ‘unipotent’ stem cell differentiates into one cell type; for
instance, a muscle stem cell differentiating into a mature muscle cell [4]. The ‘oligopotent’
stem cell, which includes the hematopoietic stem cell, differentiates into few, but not all, cell
types within a specific tissue [5]. For example, human breast stem cells are organ-specific
adult stem cells and can differentiate into the cell types within the breast tissue, negating
teratoma formation when injected into an animal model [6,7]. Unfortunately, these adult
stem cells have been shown to give rise to breast carcinomas, supporting the stem cell theory
of carcinogenesis [8]. The ‘multipotent’ stem cell differentiates into all cell types from a
specific germ layer, which includes the increasingly popular mesenchymal stem cell (MSC)
[9,10]. The ‘pluripotent’ stem cell, made famous by the fervently investigated embryonic
stem (ES) cell [11,12] and the induced pluripotent stem cell (iPS) [13], is able to
differentiate into cells of all three germ cell layers: mesodermal, endodermal and
ectodermal. Stem cell pluripotency is widely determined utilizing the classical ‘teratoma
assay’ as this is believed to provide the most concrete evidence of their capacity for
tripoblastic differentiation. Recently, investigators have challenged this scientific
cornerstone, arguing that not only is the teratoma assay not standardized, but there exist
various alternatives, including the detection of classical markers of pluripotency and in vitro
spontaneous and induced differentiation, to detect developmental potential [14]. Finally, the
‘totipotent’ stem cell, the most primitive stem cell most commonly known as the zygote, is
capable of differentiation into embryonic and extra-embryonic cell types and gives rise to
entire organisms [15,16]. Pluripotent stem cells have emerged as the variety of stem cells
most worthy of investigation through their potential regenerative and therapeutic
applications; however, they face a significant obstacle, which has thus precluded their
translational use.
Pluripotent stem cells characteristically give rise to teratoma formation through their
propensity for uncontrolled self-renewal and tripoblastic differentiation. Such has been the
burden borne by investigators of ES and iPS cells in recent years, hindering the the
therapeutic potential of these cells and quickly halting clinical trial. Recently, a population
of pluripotent stem cells has been discovered with the potential to lift this encumbrance.
Multilineage Differentiating Stress Enduring (Muse) cells were isolated under severe
cellular stress conditions, from human bone marrow and dermal fibroblasts retaining self-
renewing properties despite their lack of teratoma formation when injected into immune-
deficient mice [17]. Muse cells have since been isolated from human adipose tissue
lipoaspirates [18], commercially available adipose stem cells (ASCs) [19] and goat
fibroblasts [20]. Amongst a plethora of attractive qualities demonstrated by Muse cells,
controlled proliferation in the absence of teratoma formation sets them apart from ES and
iPS cells and offers an innovative and exciting avenue of exploration for the potential
Simerman et al. Page 2
Expert Opin Biol Ther. Author manuscript; available in PMC 2014 July 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
applications of these pluripotent stem cells to treat various human diseases. This review
traces the origin of Muse cells and their emergence into the stem cell arena, detailing their
various unique characteristics and future avenues of their application and investigation.
2. Mesenchymal stem cells
MSCs, of mesodermal lineage, are found in various mesenchymal tissues, including bone
marrow, adipose and umbilical cord, and exert both trophic and anti-inflammatory effects in
the event of tissue damage [21-26]. Despite their common consideration as a ‘mulitpotent’
stem cell population merely capable of differentiating into cell types of mesodermal origin,
MSCs have been considered attractive and viable stem cell sources for regenerative
medicine due to their accessibility, abundance and lack of tumorigenic propensity [27].
MSCs have been shown to differentiate across all three germ cell lineages with varying
efficiencies both in vitro and in vivo, contributing to tissue regeneration and repair in some
cases [28]. A total of 354 clinical trials have been conducted so far to investigate the
potential application of autologous MSCs for stem cell therapy since 1995. Clinical trials for
cancer, diabetes, multiple sclerosis, bone and cartilage disease, brain disease, heart disease,
lung disease, graft versus host disease, liver disease, Crohn’s disease, spinal cord injury and
other disorders at various phases are in progress; however, safety issues and tumor
formation in a few cases preclude wider clinical application [29].
3. Embryonic and induced pluripotent stem cells: a shift in perspective
In the early 1980s, ES cells derived from human blastocytes demonstrated the potential to
revolutionize the field of regenerative medicine, and thereby, treat a exhaustive list of
previously irreversible disorders through their capacity to generate tissues of all three germ
lines [11,12,30]. Their unlimited proliferative power as well as their ability to remain in an
undifferentiated state in cell culture conditions for 4 – 5 months created a wave of intrigue
that carried over into the mid 2000s. However, evidence soon emerged that ES cells produce
immunorejection upon transplantation and form teratomas as a result of their unlimited
proliferative capacity [31]. These hindrances to the translational use of ES cells along with
debates surrounding the bioethical issues concerning the usage of human embryos
essentially removed ES cells from the forefront of regenerative medicine.
Solving the ethical dilemmas surrounding the use of ES cells toward cell therapy, iPS cells
became the new subject of interest in the stem cell field [13,32]. iPS cells have the capacity
to reprogram, through an intricate mechanism involving the introduction of the so-called
‘Yamanaka factors’, including Nanog, Oct , Sox2, c-Myc and Klf4, which subsequently
became the characteristic markers that establish pluripotency: the ability to self-renew and
generate cells from the three germ lines and thus form teratomas [13,33-35]. Though iPS
cells resolve the concerns of immunorejection because they can be generated from a
patient’s own, or autologous, cells. They seem also to obviate ethical issues that hinder the
use of stem cells extracted from human embryos. Yet the production of teratomas upon
transplantation as a result of unbridled cell proliferation, as well as an extremely low
survival rate for both iPS and ES cells upon reintroduction to the host organism, impede the
translational use of these cells [36,37]. Integration of viral transgenes into the host genome
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of iPS cells increases the risk of tumor formation and has led to the exploration of
alternative avenues of programming, including the use of adenovirus vectors and plasmids
[38,39]. Recently, efforts have been made to improve iPS cell generation, specifically to
eliminate transgene integration and increase programming efficiency, including the
induction of fewer transcriptional factors and direct delivery of reprogramming proteins
[40,41]. Mature iPS cells have been found to possess that mature iPS cells possess an
epigenetic memory, defined by the remnants of post-translational histone and DNA
modifications, preventative of entirely successful reprogramming, often restricting their
physiological function to that of a cell within the same lineage as the original stem cell
source [34,42,43]. This phenomenon may be attributable to an organ-specific adult stem cell
origin [44,45]. Despite momentous efforts invested in the study of both ES cells and iPS
cells, little progress has come in resolving in resolving the defects that stand in the way of
the use of these stem cells toward cell therapy in humans. Consequently, there exists a
demand for a pluripotent stem cell population with a high post-transplantation survival rate
that does not undergo teratogenesis in vivo.
4. Adult pluripotent stem cells
Various populations of adult pluripotent stem cells have been put forth as potential
candidates for application in regenerative medicine, but have been subsequently scrutinized,
and in most cases, outright challenged. In 2002, multipotent adult progenitor cells (MAPCs),
derived from bone marrow, were reported to differentiate into all three embryonic germ cell
layers both in vivo and in vitro without forming teratomas to contribute to chimeric offspring
when injected into a mouse model and to regenerate tissue in the wake of myocardial
infarction [46,47]. However, investigators have found it exceedingly difficult to replicate
these data, thus putting to question the validity of these cells. Soon after the controversial
advent of MAPCs, investigators isolated human marrow-isolated adult multilineage
inducible cells, which too exhibited the potential for tripoblastic differentiation without
teratoma formation [48]. However, it is unclear how MAPCs differ from other MSCs
isolated from bone marrow [49]. Another population of adult pluripotent stem cells, termed
very small embryonic-like stem cells (VSELs), met a similar fate to MAPCs soon after their
advent. VSELs, isolated from bone marrow and umbilical cord blood, were also said to be
pluripotent and not form teratomas [50]. However, the existence of a truly pluripotent
population of VSELs was quickly refuted upon further investigation [51]. Unrestricted
somatic stem cells (USSCs), derived from umbilical cord blood, emerged in 2011, boasting
tripoblastic differentiation potential without the molecular backing of pluripotent stem cell
marker expression [52]. As USSCs were shown to express epigenetic features of pluripotent
stem cells and were able to maintain an uncommitted state, they have been proposed as a
possible avenue for iPS cell generation as well as for application in regenerative therapy
[52].
Most recently, it has been shown in mice that a method of pH reduction, termed stimulus-
triggered acquisition of pluripotency (STAP), indeed confers pluripotency to somatic cells
by a not yet well understood reprogramming phenomenon. Obokata et al. showed that
exposing splenic CD45+ lymphocytes to pH 5.7, followed by incubation with leukemia
inhibitory factor, confers pluripotency and ‘stemness’ after 7 days in culture [53]. Despite
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the fact that STAP cells appear to demonstrate a limited capacity of self-renewal, they form
teratomas, falling into a similar category as ES and iPS cells, and thus, impeding their
clinical and translational value. Further investigation must be pursued in order to elucidate
the mechanism behind the advent of these cells.
5. The emergence and characterization of Muse cells
The definition of ‘pluripotency’ relies upon a cell’s ability to differentiate into the three
embryonic germ layers [54]. When applied to stem cells in particular, this definition
encompasses the capacity for self-renewal as well. In most cases, cell pluripotency is often
both a blessing and a curse as the faculty for tripoblastic differentiation and self-renewal is
frequently uncontrolled and often materializes in teratoma formation. Such is the case with
ES and iPS cells, hindering the exploitation of their pluripotency for regenerative purposes.
In 2010, a research team at the Tohoku University in Sendai, Japan, successfully isolated a
population of pluripotent MSCs from bone marrow aspirates and human skin fibroblasts
through the induction of severe cellular stress, from bone marrow aspirates and human skin
fibroblasts. Termed Muse cells, this cell population expresses the pluripotency marker stage-
specific embryonic antigen-3 (SSEA-3) as well as the mesenchymal marker CD105 [17].
When cultured in suspension, Muse cells form cell clusters analogous to ES cell-derived
embryoid bodies [17]. In isolating stem cells from human adipose tissue lipoaspirates,
imposing alternate, yet increasingly severe stress conditions, our research team at the
University of California, Los Angeles, discovered morphologically identical cell clusters
that are recognized by pluripotent stem cell markers (unpublished data, Chazenbalk, 2008).
Upon further investigation, these cells too proved to be the SSEA-3/CD105-positive Muse
cells, distinguished as Muse cells derived from adipose tissue (Muse-AT) [18], which had
previously been described in bone marrow aspirates and skin fibroblasts [17]. More recently,
investigators have shown that Muse cells can be isolated from intact human adipose tissue
and commercially available human ASCs through SSEA-3 cell sorting techniques [19].
Muse-AT cells have been subjected to extensive immunocytochemical analysis as well as
microarray analysis to assess their morphological and functional properties. Similar to Muse
cells derived from bone marrow aspirates and skin fibroblasts [17], Muse-AT cells grow in
suspension as cell clusters reminiscent of ES cells and in addition to SSEA-3 express the
classic pluripotency markers Sox2, Oct3/4, Nanog, TRA-1-60 and TRA-1-81 (Figure 1)
[17,18]. Muse-AT cells, like Muse cells derived from bone marrow aspirates and skin
fibroblasts, can differentiate into mesodermal, endodermal and ectodermal embryonic germ
lineages spontaneously and with the use of tissue-specific culture media [17,18,55].
Immunocytochemistry studies showed that Muse-AT cells express markers for adipocytes,
myocytes, hepatocytes and neural cells in both naive and induced Muse-AT cells, supporting
both spontaneous and induced tripoblastic differentiation [18]. They have been shown to
differentiate into cells of mesodermal, endodermal and ectodermal lineage spontaneously,
with 23, 20 and 22% respective efficiencies and under induction, with 82, 75 and 78%
respective efficiencies, in vitro, exhibiting morphological characteristics of each lineage
after a mere 3 days in culture. Muse-AT cells demonstrated formation of lipid droplets when
induced to differentiate into adipocytes, characteristically fused nuclei and smooth muscle
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striations when induced to differentiate into myocytes, and long, finger-like projections,
typical of neurons, when induced to differentiate into neural cells (Figure 1) [18].
6. Nontumorigenicity of Muse cells
Despite their delineation as pluripotent stem cells, Muse cells exhibit both low proliferative
and telomerase activities, a normal karyotype as well as asymmetric growth, and thus, do not
undergo tumorigenesis or teratoma formation when transplanted into a host organism
[17,19]; unpublished data, Heneidi 2013) (Figure 2). While both the necessity and validity
of the teratoma assay as an indicator of true pluripotency has been challenged in recent
years, tumor formation has typically been considered to go hand-in-hand with both
pluripotency and self-renewal [14,56-58]. Muse cells do not undergo unbridled proliferation
or tumor formation, setting them apart from ES and iPS cells. When transplanted into the
testes of immune-deficient mice, Muse cells did not form teratomas, while ES cells formed
large teratomas within 8 – 10 weeks [19]. As pluripotency and tumorigenesis have
commonly been considered two sides of the same coin, this begs the question as to what
factors allow Muse cells to avoid tumor formation while retaining their capacity for
differentiation into all three germ lineages. Low telomerase activity, in part, is responsible
for this scientific anomaly [19].
Muse cells exhibit a slight increase in expression of Sox2, Nanog, Oct3/4 as compared with
non-muse cells and to ASCs (twofold to fourfold) [17,18]. Interestingly, Muse cells have
much lower expression of the so-called ‘Yamanaka factors’ in comparison with iPS cells (>
105 fold decrease) [55]. This intermediate expression of the genes that have been shown to
confer pluripotency and teratogenesis may explain how Muse cells retain their lineage
plasticity while simultaneously negating teratoma formation.
It is well established that Lin28, a RNA-binding protein gene, functions to maintain both
pluripotency and tumorigenesis in ES and iPS cells. Let-7, a microRNA that regulates
embryonic development, cell differentiation and tumor suppression, has the opposite effect
[59]. While overexpression of Let-7 blocks Lin28 gene expression, strong Lin28 expression
degrades Let-7, maintaining a ‘yin yang’ balance [59]. Initial studies found that Let-7 was a
critical factor in the global decrease of microRNA, which has been observed in numerous
cancers [59]. In contrast, ES and iPS cells have a very high Lin28/Let7 ratio, which is
believed to lead these cells, in part, on a pathway to tumorigenic proliferation and,
subsequently, cancer [59]. Interestingly, Muse cells retain their pluripotent capacity in the
absence of a strong Lin28 influence (> 105 fold decrease in comparison with iPS cells) [55].
Furthermore, Let-7 seems to be a critical master regulator of cell proliferation in preventing
Muse-AT cells from forming teratomas (unpublished data, Chazenbalk, 2013).
Overexpression of Let-7 in Muse cells could potentially play a critical role in inhibiting
Lin28 expression, and therefore, would protect these cells from tumorigenic proliferation
and teratoma formation after transplantation in vivo. Transgenic overexpression of Let-7 in
Muse cells is a putative target for further exploration.
Cyclin-dependent kinase inhibitor 2A (CDKN2A), a key tumor suppressing factor, is
another interesting gene found in Muse-AT cells that may provide insight into this intriguing
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association. CDKN2A is tightly linked with p16INK4a, which function together as a tumor-
suppressing complex [60]. Repression of this complex promotes the isolation of cells in
breast tissue with a high degree of lineage plasticity, low telomerase activity and the
propensity for tumor formation [61]. Interestingly, CDKN2A is expressed in Lin28-negative
Muse-AT cells, which reap the benefits of the pluripotency, nontumorigenicity and low
telomerase activity. Upon further investigation, this genetic combination may illuminate the
mechanism behind the pluripotent cell plasticity and tumor suppression exhibited by Muse
cells.
7. Awakening Muse cells from quiescence
The application of stem cells in regenerative medicine has often been impeded by a low
survival rate, typically < 3%, when exposed to the high-stress engraftment environment
[62-64]. The harsh milieu of the recipient site is exacerbated in instances of acute injury,
which includes myocardial infarction, ischemic injury and stroke, hindering cell survival
and, in some cases, inducing unwanted differentiation [65,66]. Previously, investigators
have employed various tactics to acclimatize stem cells to pro-apoptotic factors, including
hypoxia, malnutrition, pro-inflammatory cytokines, and reactive oxygen and nitrogen
species, in order to enhance stem cell survival in vivo. Hypoxia preconditioning, a process in
which stem cells are introduced to hypoxic conditions for 24 – 48 h prior to transplantation,
has been shown to increase their likelihood of survival [67,68]. However, as the induction of
a high-stress environment is imperative to Muse cell activation from their quiescent state,
they are inherently conditioned to endure and thrive when transplanted in vivo [17,18]. Muse
cells were most efficiently isolated from bone marrow aspirates and skin fibroblasts utilizing
a long-term trypsin incubation, or proteolytic digestion, of the tissue [17]. Alternatively,
subjecting human adipose tissue lipoaspirate material to even severe cellular stress (long-
term exposure to the proteolytic enzyme collagenase, serum deprivation, low temperatures
and hypoxia) yielded a highly purified population of Muse-AT cells [18]. The innate
endurance of Muse cells to a high-stress environment supports their capacity for survival
and the ultimate translational objective of tissue regeneration in vivo.
Muse cells, prior to cellular stress disruption, are present in a quiescent state under normal
physiological circumstances within the cellular niche [17,18]. Multiple adult stem cell line-
ages have been shown to exist in a quiescent state at various time points throughout their
lifespan, including hematopoietic stem cells and epithelial stem cells, which allegedly play a
role in the preservation of their self-renewal [69]. Quiescence functions in the maintenance
of malignancy in cancer stem cells and contributes to the susceptibility for cancer relapse
notwithstanding cancer treatment [69]. Quiescent stem cells, including Muse-AT cells, are
mobilized by the disruption of the cellular niche attributed to CXCL2, a critical chemokine
involved in stem cell homing [70]. CXCL2, overexpressed in cancer cells, contributes both
to cancer cell survival and malignancy. Studies show that preconditioning MSCs with
CXCL2 increases post-transplantation survival rates after myocardial infarction [70].
CXCL2 is expressed 770 folds higher in Muse-AT cells as compared with ASCs and could
therefore explain the inherent resistance of Muse-AT cells to cellular stress from a genetic
perspective [18].
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Our microarray data, showing up- and downregulation of 144 critical genes involved in cell
death and survival (e.g., SGK1, MDH1, ATF2, HSPA8, PDIA3, BRD1, CALM1, NR4A2,
GATA2, CDK6, NUF2, CDK6, BRC1, BUB1B and CCXL2), suggest that significant
fluctuation in expression of these genes could be required to activate Muse cells from
quiescence [18]. Furthermore, Muse-AT cells overexpress ALDH1A2 (47-fold change
versus ASCs) and SOD2 (41-fold change versus ASCs), which boast antioxidative stress and
antiapoptotic functions [70-72]. Interestingly, DNA repair genes are generally upregulated
in Muse-AT cells, indicating a high capacity to resist DNA damage at the hands of cellular
stress [18].
8. Muse cells and tissue regeneration
Green fluorescent protein (GFP)-labeled Muse cells injected intravenously into damaged
skin, muscle and liver tissue of immune-deficient mice were able to differentiate accordingly
in vivo and contribute vastly to tissue regeneration within 2 – 4 weeks of engraftment [17].
Muse cells integrated into and formed dermis, gastrocnemius muscle and liver tissue
(Figure 3) [17]. Furthermore, Muse cells were shown to treat fulminant hepatitis, muscle
degeneration and skin injury in a mouse model (Figure 3). Integrated Muse cells were
detected and tracked by lentivirus-GFP and human anti-Golgi complex immunoreactivity,
human albumin and antitrypsin in the fulminant hepatitis model, human dystrophin in
degenerated muscle and cytokeratin 14 in injured skin [17].
It has been shown that mature melanocytes derived from Muse cells have the capacity to
contribute to tissue regeneration after grafting into the damaged skin of a mouse model [73].
Muse cells were utilized to create 3D cultured skin in vitro, which was then transplanted in
vivo to the back skin of immune-deficient mice. Muse-derived melanocytes were pigmented,
as compared with the negative control, and tested positive for human melanocyte markers
(Figure 3). These studies suggest that Muse cells may be an ideal candidate population for
autologous transplantation to treat melanocyte dysfunctions such as vitiligo.
9. Muse cells and the immune system
In adipose tissue, Muse-AT cells reside with both the adipocyte and the stromal vascular
fractions, and presumably interact with both ASCs and adipose tissue macrophages (ATM)
[18]. It has been shown that cross-talk between ASCs and ATM contributes to cell plasticity,
the maintenance of quiescence, adipogenesis and ASC formation [74]. On the other hand, it
is well known that adipose tissue is immunologically dynamic, in which there exist different
types of leukocytes such as CD4+ and CD8+T cells, T regulatory (Treg) cells, macrophages
and B lymphocytes, each of which play a versatile role in inflammation and
immunometabolism [75]. Therefore, ASC and adipose immune cell interaction with
neighboring Muse-AT cells may have implications for their lineage plasticity, adipose tissue
differentiation, tissue repair and the production and recruitment of signaling molecules in
times of cellular stress, acute damage and dysregulated metabolism [18].
The development of immunosuppressive drugs has made possible the treatment of several
autoimmune disorders and cell and solid organ transplantation. However, chronic
immunosuppression leads to detrimental effects, including susceptibility to infection, renal
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failure, diabetes, ulcers and risk of tumorigenesis [76]. Therefore, novel, effective and
specific immunosuppressors without deleterious effects must be developed for clinical use.
Numerous studies have demonstrated that MSCs possess immunosuppressive properties and
modulate the function of a wide range of immune cell subpopulations of both the innate and
the adaptive arms of the immune system, including T and B lymphocytes, natural killer and
dendritic cells and induced Treg lymphocytes both in vivo and in vitro. This
immunomodulatory role of MSCs has been attributed to both their capacity to synthesize
and release soluble mediators and establish cell-to-cell contact with target cells. Several
MSC-derived messengers have been identified as responsible for the mediation of
immunomodulatory activity on T cell responses such as indoleamine 2,3-dioxygenase
(IDO), prostaglandin E2, TGF-β, hepatocyte growth factor, TNF-α stimulated gene/protein
6, and NO [77-82]. It is known that human MSCs inhibit T cell proliferation in vitro, a
process that does not require major histocompatibility complex (MHC) restriction [83] but
rather depends on the pro-inflammatory environment [84], where the IDO pathway seems to
play a pivotal role [85] as well as HLA-G5 and IL-10 by cell contact [86]. Moreover,
suppression of T lymphocyte proliferation exerted by MSCs also occurs through other
mechanisms in which the cytokine microenvironment seems to play a decisive role.
Importantly, if MSC-mediated immunosuppression does not require MHC restriction, one
might speculate that it would be possible to use allogeneic MSCs to prolong the lifespan of
transplanted organs or to treat autoimmune disorders.
ES cells have also shown a comparable ability to downregulate a T cell-mediated immune
response via the arginase-dependent pathway [87]. However, the immunogenicity of ES
cells and MSCs has been questioned as it has been demonstrated using noninvasive
molecular imaging techniques that human ES cell xenotransplantation was rejected in
immune-competent mice [88]. Therefore, it is clear to conclude that ES cells and MSCs are
very efficient in modulating an immune response in vitro and in vivo. However, ES cell and
MSC immunogenicity is a major concern and further studies must be performed to clarify
this issue.
In this respect, we are currently planning experimental studies to address whether human
Muse-AT cells have an immunomodulatory capacity as well as immunoprivileged features
using both immune-deficient and immune-competent mice. As previously described, Muse-
AT cells overexpress key molecules responsible for cell homing and cell-to-cell connections
between immune cells such as CXCL2 and intercellular adhesion molecule 1 (ICAM1) [18].
CXCL2, also called macrophage inflammatory protein 2-α, is implicated in neutrophil
recruitment as an early step in controlling tissue injury and infections [89]. ICAM1, also
known as CD54, a member of the immunoglobulin superfamily, is significantly increased
upon cell activation, functions in signal transduction with pro-inflammatory effects, and is
involved in inflammation and leukocyte extravasation. ICAM1 binds to macrophage
adhesion ligand-(Mac)1, CD11a/CD18 (LFA-1) and CD11c/CD18 [90]. We have also found
that Muse-AT cells exclusively express specific CD genes, as opposed to ASCs, which
allow distinguishing both cell types based on their immunophenotype characteristics [18].
Furthermore, Muse-AT cells express three connexin genes GJA4, GJB2, GJB4, as well as
C1orf71 (CNST) [18]. C1orf71 encodes the connexin recycling protein, Consortin, which
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mediates gap junction recycling and degradation [91]. Thus, additional studies are warranted
to determine the role of these molecules on the surface of Muse-AT cells and their
interaction with immune cells. The fundamental knowledge obtained by tackling these and
other important questions should accelerate progress in the field and will ultimately lead to
the development of novel immune therapeutics to control allogeneic cell and organ
acceptance, ameliorate autoimmunity and improve metabolic complications.
10. Muse cells as a source of iPS cells
In addition to the notion that iPS cells are derived from organ-specific adult stem cells
[44,45], it has been reported that in adult human fibroblasts iPS cells are generated
exclusively from Muse cells, supporting the elite model of iPS cell generation rather than the
stochastic model [55]. The stochastic model posits that iPS cells can be generated from
every cell type, with varying efficiencies, through the induction of the Yamanaka factors
[13]. In support of the stochastic model, investigators have described the highly specific
process through which cells are reprogrammed to iPS cells, detailing the molecular and
genetic changes required for the induction of this process in any type of cell [92].
Conversely, the elite model conjectures that iPS cells can only be generated by a specific
subset of cells [13]. When fibroblasts were subjected to transduction of the Yamanaka
factors, only Muse cells underwent successful iPS cell generation [55]. Gene analysis shows
that classical markers of tumorigenesis, including BCR1, CCMB1 and CCMB2, are highly
expressed in iPS cells derived from Muse cells as compared with naive Muse cells [55]. In
contrast, CDKN1A and CDKN2A, involved in tumor suppression, are highly expressed in
Muse cells versus iPS cells derived from Muse cells [55]. This may shed light on the effects
of the induction of the Yamanaka factors and their contribution to tumorigenesis and the
propensity for teratoma formation inherent in iPS cells but not in Muse cells; however,
further studies are required to elucidate this distinction.
11. Muse cells in different species
There currently exists a single report regarding the isolation of Muse cells from an animal
model. Liu et al. isolated SSEA+ Muse cells from goat skin fibroblast cells (SFC) by FACS
in order to investigate their application for somatic cell nuclear transfer (SCNT) [20]. They
demonstrated that 2 – 4% of SFCs are SSEA+ Muse cells and that when applied as donor
cells for SCNT, Muse cells contributed to a higher blastocyst rate than SSEA- SFCs in
cloned embryos. Furthermore, blastocysts from donor Muse cells demonstrated enhanced
quality as determined by total cell number and rate of apoptosis [20]. Confirming the
existence of Muse cells in other mammalian species is a major step in the investigation of
their potential and will undoubtedly inspire further animal studies to demonstrate their
applicability for stem cell therapies.
12. Future directions: Muse cells in regenerative medicine
While investigators have adequately demonstrated the potential carried by Muse cells, it is
now of the utmost importance to exploit this potential to explore various avenues of their
translational application for regenerative medicine. As Muse-AT cells are so painlessly and
efficiently isolated, one intriguing avenue is the formation of pluripotent stem cell banks for
Simerman et al. Page 10
Expert Opin Biol Ther. Author manuscript; available in PMC 2014 July 16.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
regenerative purposes. Harvesting and collecting Muse cells for the purpose of autologous
stem cell therapies could prove useful for the regeneration of any type of tissue present in
the human body and for the treatment of an exhaustive list of diseases, including
neurological and immune disorders, and acute injuries to critical organs such as the heart
and the brain. Furthermore, as a product of their undeniable genetic and physiological
similarities, Muse cells have the potential to elucidate new avenues of cancer research,
specifically with regards to cancer stem cells, quiescence, malignancy and post-treatment
relapse [18,69]. Finally, as a feature of their high resistance to cellular stress, Muse cells
could shed light on antiaging mechanisms and the rejuvenation of various tissues and organs
facing age-related degeneration. It is commonly understood that the aging of human tissue
coincides with an increase in oxidative stress damage to tissues as a consequence of an
accumulation of free radicals and reactive oxygen species [93-96]. Moreover, DNA
degradation and mutation contribute to the increasingly harsh milieu of the aging body. As
Muse cells are inherently resistant to cellular stress, and genetically resilient to DNA
damage, their application for the investigation of age-related and degenerative diseases is
both relevant and promising.
Recently, pluripotent stem cells have been put forth as a promising tool for drug discovery,
as they are said to model human physiology in a manner that may provide insight into the
translational value of drugs in the early stages of screening [44,97,98]. It has been shown
that various diseases can be successfully detected in differentiated adult pluripotent stem
cells in vitro, providing a model for drug treatments [99]. iPS cells have been employed for
this purpose; however, as their genetic reprogramming capacity remains under scrutiny,
there exists a void that Muse cells have the potential to fill. Because Muse cells are ‘natural
pluripotent stem cells’ present in every tissue of the body, they can be assessed at every
stage of differentiation, from progenitor to terminally differentiated cell, allowing the full
scope of a drug’s cellular impact to be studied. Negating the induction of genetic
manipulation, Muse cells are excellent candidates for use towards drug discovery.
Muse cells have emerged as a source of boundless investigation and innovation, revitalizing
the conversation surrounding the application of pluripotent stem cells in regenerative
medicine.
13. Expert opinion
Muse-AT cells, as compared with Muse cells isolated from alternate sources throughout the
body, present themselves as the most promising stem cell source for application in
regenerative medicine. Practically speaking, lipoaspirate material is easily accessible,
abundant, and painlessly, routinely, and noninvasively extracted from the human body for
both medical and cosmetic purposes. Previously, investigators have been hindered by a low
yield of Muse cells from other sources, including dermal fibroblasts and bone marrow, as
Muse cells make up only 1 – 3% of adult tissue. Hundreds of millions of adipose cells can
be extracted from a mere 1 – 2 liters of tissue, enhancing the number of extractable Muse-
AT cells. The isolation procedure, a 16-h digestion in a proteolytic enzyme under serum
deprivation, low temperatures and severe hypoxia, is both time-efficient and cost-effective,
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negating the necessity for cell sorting techniques, which require expensive reagents and
equipment.
As described above, Muse-AT cells posses an intrinsic predisposition for tripoblastic
differentiation without teratoma formation, unlike pluripotent ES and iPS cells. Exposing
Muse-AT cells to the same culture conditions used to induce ES and iPS differentiation into
hepatocytes results in the formation of hepatocyte-like cells. Similarly, Muse-AT cells
differentiate into neural cells in a comparable manner to ES and iPS cells. These results
suggest that the potential of Muse-AT cells to treat disorders of the liver and brain parallel
that of both ES and iPS cells; however, negating transgenic induction, they present zero
teratogenic risk. Furthermore, Muse-AT cells exhibit medial to low expression of many
genes involved in tissue development, cellular assembly and organization, cellular function
and maintenance, DNA replication, repair and cell cycling, indicative of their intrinsic lack
of tumorigenic susceptibility. As previously described, Muse-AT cells express genes
associated with cell death and survival, as opposed to their ASC neighbors, indicating a
genetic predisposition to the transition from the quiescent to the active state as a
consequence of severe cellular stress.
According to microarray analysis performed on Muse-AT cells, they differentially express
genes from the following functional groups in order of decreasing significance: cell death
and survival, embryonic development, organismal development, tissue development, cellular
assembly and organization and cellular function and maintenance (Figure 4). Many of these
genes are highly conserved, with homologues present in numerous primordial organisms
including yeast, Saccharomyces cerevisiae, Caenorhabditis elegans, Chlamydomonas, Trixis
californica and Drosophila [18]. This suggests that Muse cells may function according to a
highly conserved cellular mechanism related to cell survival in response to severe cellular
stress, as well as the functional regeneration of damaged tissues and amputated limbs in
primitive species [66,100].
As Muse-AT cells have been thoroughly assessed for their pluripotency as well as their
cellular stress resistance, and are so practically accessible, we believe them to be the strain
of Muse cells most promising for the investigation of adult, nontumorigenic, pluripotent
stem cells, and the eventual translation to regenerative stem cell therapy.
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Article highlights
• Pluripotent stem cells have the potential to revolutionize regenerative therapy
• The application of many pluripotent stem cells, such as embryonic and induced
pluripotent stem cells, for treatment in humans is impeded by characteristic
teratoma formation.
• Multilineage Differentiating Stress Enduring (Muse) cells exhibit pluripotent
characteristics, including controlled self-renewal and tripoblastic differentiation.
• Muse cells do not form teratomas when transplanted in vivo.
• Muse cells derived from adipose tissue are the most efficiently isolated and
applicable form of Muse cells in regenerative medicine.
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Figure 1. Multilineage Differentiating Stress Enduring (Muse) cell characterization by
pluripotency markers and morphology
Immunostaining indicates that Muse cells express the pluripotency markers: (A) stage-
specific embryonic antigen-3, (B) OCT3/4, (D) SOX2 and (E) Nanog. (C) Muse cells
derived from adipose tissue (Muse-AT) cells grow in suspension, forming cell clusters as
well as individual cells (red arrows). (F) Muse-AT cells were grown as adherent cells in the
presence of myocyte differentiation medium. Formation of myocytes was detected using an
antihuman MSA antibody. Nuclei were stained with DAPI (blue). (G) Muse-AT cells were
grown as adherent cells in the presence of hepatocyte differentiation medium. Formation of
hepatocytes was detected using an antihuman a-fetoprotein antibody. Nuclei were stained
with DAPI (blue). (H) Isolated Muse-AT cells were grown for 7 days as nonadherent cells
and then cultured for an additional 7 days as adherent cells. Neural-like cells were detected
by immunofluorescence using an antihuman MAP2 antibody. Nuclei were stained with
DAPI (blue). (Original magnification was 600× for figures F – H).
Reproduced from [18].
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Figure 2. Nontumorigenicity of Multilineage Differentiating Stress Enduring (Muse) cells
(A) Embryonic stem cells infused into immunodeficient mice (SCID mice) testes, formed
teratomas within 8 – 12 weeks. Histological analysis showed that the teratoma contained (B)
muscle tissue, (C) intestine-like structure and (D) keratinized skin. (E) Muse cell-
transplanted testes did not generate teratomas similar to untreated testes. (F,G) Testis
injected with Muse cells maintained normal structure even 6 months postinjection. (H) Muse
cells derived from adipose tissue cells showed normal karyotype. Scale bars = 100 μm.
Reproduced from [17].
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Figure 3. Multilineage Differentiating Stress Enduring (Muse) cells integrated into damaged
tissue
GFP-positive human Muse cells integrated into a (A) skin injury model, (B) spinal cord
injury model, (C) fulminant hepatitis model, and (D) a degenerated muscle model. GFP-
Muse cells were positive for (A) cytokeratin 14, (B) neurofilament albumin, (C) trypsin and
(D) dystrophin. Muse cells were also positive for the human cell marker, antihuman Golgi
complex, confirming that the positive cells were of human origin. Scale bars = 50 μm (A, B)
and 100 μm (C, D).
GFP: Green fluorescent protein.
Reproduced from [17].
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Figure 4. Identification of the top 10 functional groups of all differentially expressed genes
(twofold or higher) in Muse cells derived from adipose tissue (Muse-AT) cells versus adipose
stem cells (ASCs)
Fischer’s exact test was used to calculate a p-value determining the probability of the
association between the genes in the data set with functional groups and canonical pathways.
Functional groups are displayed along the x-axis, while the y-axis displays logarithm of p
values calculated by Fisher exact between the ratio of the number of genes differentially
expressed genes (twofold or higher) in Muse-AT versus ASCs in a given functional group or
pathway divided by total number of genes that make up that functional group or pathway
with a threshold for statistical significance set at 0.05. The analysis was performed by
Ingenuity Pathways analysis software.
Reproduced from [18].
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